Theravance Biopharma Inc. (NASDAQ:TBPH) went down by -12.88% from its latest closing price compared to the recent 1-year high of $22.74. The company’s stock price has collected -11.22% of loss in the last five trading sessions. Press Release reported on 01/10/22 that Theravance Biopharma, Inc. Announces Enrollment -2-
Is It Worth Investing in Theravance Biopharma Inc. (NASDAQ :TBPH) Right Now?
Plus, the 36-month beta value for TBPH is at 0.80. Opinions of the stock are interesting as 2 analysts out of 8 who provided ratings for Theravance Biopharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $10.14, which is -$1.04 below the current price. TBPH currently public float of 60.55M and currently shorts hold a 5.51% ratio of that float. Today, the average trading volume of TBPH was 984.13K shares.
TBPH’s Market Performance
TBPH stocks went down by -11.22% for the week, with a monthly jump of 14.58% and a quarterly performance of 40.03%, while its annual performance rate touched -34.16%. The volatility ratio for the week stands at 8.76% while the volatility levels for the past 30 days are set at 6.92% for Theravance Biopharma Inc.. The simple moving average for the period of the last 20 days is -0.80% for TBPH stocks with a simple moving average of -13.95% for the last 200 days.
Analysts’ Opinion of TBPH
Many brokerage firms have already submitted their reports for TBPH stocks, with JP Morgan repeating the rating for TBPH by listing it as a “Neutral.” The predicted price for TBPH in the upcoming period, according to JP Morgan is $12 based on the research report published on November 05th of the previous year 2021.
JP Morgan, on the other hand, stated in their research note that they expect to see TBPH reach a price target of $7. The rating they have provided for TBPH stocks is “Underweight” according to the report published on September 15th, 2021.
Morgan Stanley gave a rating of “Underweight” to TBPH, setting the target price at $14 in the report published on August 25th of the previous year.
TBPH Trading at 17.17% from the 50-Day Moving Average
After a stumble in the market that brought TBPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.92% of loss for the given period.
Volatility was left at 6.92%, however, over the last 30 days, the volatility rate increased by 8.76%, as shares surge +11.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.63% upper at present.
During the last 5 trading sessions, TBPH fell by -11.22%, which changed the moving average for the period of 200-days by -45.80% in comparison to the 20-day moving average, which settled at $11.31. In addition, Theravance Biopharma Inc. saw 1.00% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TBPH starting from WORBOYS PHILIP D, who sale 8,829 shares at the price of $20.00 back on Mar 09. After this action, WORBOYS PHILIP D now owns 343,679 shares of Theravance Biopharma Inc., valued at $176,580 using the latest closing price.
Stock Fundamentals for TBPH
Current profitability levels for the company are sitting at:
- -414.37 for the present operating margin
The net margin for Theravance Biopharma Inc. stands at -386.90. The total capital return value is set at -90.34, while invested capital returns managed to touch -90.80. Equity return is now at value 69.40, with -53.90 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 22.46, with the company’s debt to enterprise value settled at 0.45. The receivables turnover for the company is 1.20 and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.18.